Skip to Main Content
FIB-SEM Collaboration Core (F-SCC)
YSM Home

INFORMATION FOR

Melanoma, skin, Phase I-II

A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

What is the purpose of this trial?

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with nivolumab.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jialing Zhang

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sub-Investigators

  • Last Updated
    08/29/2024
  • Study HIC
    #2000029137

Contact Information

For more information about this study, including how to volunteer, contact Jialing Zhang